United States · Funded startup

Who invested in Meta Pharmaceutical Services

2 rounds we have observed, with the one investor named in them. Every figure came from a named source, and where the company reported a raise to the SEC itself, that is shown beside it.

Funding summaryUpdated 26 Oct 2026

$14Mraised across 2 rounds since 2010, from 2 sources

$6.0MDebt$7.5MDebt
Latest round
Debt, $7.5MJul 2013
Step-upi
1.3×
Investors
1
See who backed them

The funding story

Each circle is a round, placed by date and sized by amount. The line above is the running total.

201120122013
$6.0MDebt$7.5MDebt
First round
Debt, $6.0M
Sept 2010
Biggest round
$7.5M
Debt · Jul 2013
Between rounds
2.8 years
from the last two

The rounds

  1. Jul 2013
    Debt$7.5M1 returning

    Reported by pehub.com

  2. Sept 2010
    Debt$6.0M1 new

    Reported by finsmes.com

Everyone who backed them

Praesidian CapitalPrivate equity2rounds

Missing a round, or an investor who was in one? Tell us.

Quick answers about Meta Pharmaceutical Services

Who invested in Meta Pharmaceutical Services?

Meta Pharmaceutical Services's investors include Praesidian Capital.

How much has Meta Pharmaceutical Services raised?

Meta Pharmaceutical Services has raised $14M across 2 rounds since 2010.

When did Meta Pharmaceutical Services last raise?

Meta Pharmaceutical Services's most recent round was a Debt of $7.5M in Jul 2013.

What was Meta Pharmaceutical Services's biggest round?

Its most recent round, $7.5M in Jul 2013, is also its largest on record.

Who backed Meta Pharmaceutical Services first?

Meta Pharmaceutical Services's first round on record, in Sept 2010, was backed by Praesidian Capital.

What stage is Meta Pharmaceutical Services at?

Meta Pharmaceutical Services's latest named round is a Debt, in Jul 2013.

Where is Meta Pharmaceutical Services based?

Meta Pharmaceutical Services is based in the United States.

Find investors like these

Search every investor by what they have actually funded, then narrow to your stage and market. Free.